{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:24:31Z","timestamp":1794273871304,"version":"4.9.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Homozygous loss of the 9p21 locus encompassing CDKN2A, CDKN2B, and MTAP is the most frequent copy number alteration across tumor types, making it a promising target for precision medicine strategies. To explore drug vulnerabilities exposed by this loss, we generated 9p21 locus isogenic bladder cancer (BLCA) cell models to perform a multiparametric drug screen, testing 2,349 compounds. We identified cytarabine and methotrexate as significantly more effective in the 9p21 compromised BLCA cells. Analysis of morphological alterations further supported a genotype-specific activity of nucleoside analogs, nominating gemcitabine as a drug with greater efficacy in this context. To further exploit MTAP loss, we explored drug combinations targeting MTAP synthetic lethal partners, PRMT5 and MAT2A. Synergy between cytarabine and inhibitors of PRMT5 (MRTX1719) and MAT2A (AG-270) was mediated by a differential activation of DNA damage and replication stress markers, suggesting an exploitable vulnerability. In fact, rational drug combinations with ATR\/CHK1 pathway inhibitors increased efficacy while maintaining 9p21-specificity. Finally, we confirmed the effectiveness of these combinations in cell models of pancreatic adenocarcinoma and pleural mesothelioma, two tumor types with high prevalence of MTAP loss and, most notably, in bladder cancer patient-derived organoids, underscoring the strong translational potential of our findings.<\/jats:p>","DOI":"10.1038\/s41698-026-01434-w","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T05:15:45Z","timestamp":1776489345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategies"],"prefix":"10.1038","volume":"10","author":[{"given":"Riccardo","family":"Bevilacqua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cantore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Macedo-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pancher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Radi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsetta","family":"Quaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarcisio","family":"Fedrizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Adami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lorenzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Kruithof-de Julio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishoy Morris","family":"Faltas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Demichelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"1434_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0165-4608(95)00157-3","volume":"86","author":"H Zhang","year":"1996","unstructured":"Zhang, H., Chen, Z. H. & Savarese, T. M. Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. Cancer Genet. Cytogenet. 86, 22\u201328 (1996).","journal-title":"Cancer Genet. Cytogenet."},{"key":"1434_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrm1987","volume":"7","author":"J Gil","year":"2006","unstructured":"Gil, J. & Peters, G. Regulation of the INK4b\u2013ARF\u2013INK4a tumour suppressor locus: all for one or one for all. Nat. Rev. Mol. Cell Biol. 7, 667\u2013677 (2006).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1434_CR3","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/0092-8674(95)90214-7","volume":"83","author":"DE Ouelle","year":"1995","unstructured":"Ouelle, D. E., Zindy, F., Ashmun, R. A. & Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993\u20131000 (1995).","journal-title":"Cell"},{"key":"1434_CR4","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1126\/science.aad5214","volume":"351","author":"GV Kryukov","year":"2016","unstructured":"Kryukov, G. V. et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351, 1214\u20131218 (2016).","journal-title":"Science"},{"key":"1434_CR5","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.aad5944","volume":"351","author":"KJ Mavrakis","year":"2016","unstructured":"Mavrakis, K. J. et al. Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5. Science 351, 1208\u20131213 (2016).","journal-title":"Science"},{"key":"1434_CR6","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","volume":"15","author":"K Marjon","year":"2016","unstructured":"Marjon, K. et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis. Cell Rep 15, 574\u2013587 (2016).","journal-title":"Cell Rep"},{"key":"1434_CR7","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","volume":"13","author":"LD Engstrom","year":"2023","unstructured":"Engstrom, L. D. et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer. Cancer Discov. 13, 2412\u20132431 (2023).","journal-title":"Cancer Discov."},{"key":"1434_CR8","doi-asserted-by":"publisher","first-page":"6932","DOI":"10.1021\/acs.jmedchem.4c03121","volume":"68","author":"LH Pettus","year":"2025","unstructured":"Pettus, L. H. et al. Discovery of AMG 193, an MTA-cooperative PRMT5 inhibitor for the treatment of MTAP -deleted cancers. J. Med. Chem. 68, 6932\u20136954 (2025).","journal-title":"J. Med. Chem."},{"key":"1434_CR9","doi-asserted-by":"publisher","first-page":"9531","DOI":"10.1021\/acs.jmedchem.2c00395","volume":"65","author":"C Li","year":"2022","unstructured":"Li, C. et al. Overview of methionine adenosyltransferase 2A (MAT2A) as an anticancer target: structure, function, and inhibitors. J. Med. Chem. 65, 9531\u20139547 (2022).","journal-title":"J. Med. Chem."},{"key":"1434_CR10","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1434_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t, L. et al. Bladder cancer. Nat. Rev. Dis. Primers. 9, 58 (2023).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1434_CR12","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/ng.3692","volume":"48","author":"BM Faltas","year":"2016","unstructured":"Faltas, B. M. et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat. Genet. 48, 1490\u20131499 (2016).","journal-title":"Nat. Genet."},{"key":"1434_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22465-w","volume":"12","author":"SV Lindskrog","year":"2021","unstructured":"Lindskrog, S. V. et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat. Commun. 12, 2301 (2021).","journal-title":"Nat. Commun."},{"key":"1434_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556.e25 (2017).","journal-title":"Cell"},{"key":"1434_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"1434_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","volume":"8","author":"R Zhao","year":"2016","unstructured":"Zhao, R., Choi, B. Y., Lee, M.-H., Bode, A. M. & Dong, Z. Implications of genetic and epigenetic alterations of CDKN2A (p16 INK4a) in cancer. EBioMedicine. 8, 30\u201339 (2016).","journal-title":"EBioMedicine"},{"key":"1434_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29397-z","volume":"13","author":"O Alhalabi","year":"2022","unstructured":"Alhalabi, O. et al. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat. Commun. 13, 1797 (2022).","journal-title":"Nat. Commun."},{"key":"1434_CR18","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran, A., Cookson, M. S., Guercio, B. J. & Cheng, L. Advances in diagnosis and treatment of bladder cancer. BMJ 384, e076743 (2024).","journal-title":"BMJ"},{"key":"1434_CR19","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari, R. B. et al. Combination therapy in combating cancer. Oncotarget 8, 38022\u201338043 (2017).","journal-title":"Oncotarget"},{"key":"1434_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2020.12.010","volume":"39","author":"P Kalev","year":"2021","unstructured":"Kalev, P. et al. MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage. Cancer Cell 39, 209\u2013224.e11 (2021).","journal-title":"Cancer Cell"},{"key":"1434_CR21","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 50, W739\u2013W743 (2022).","journal-title":"Nucleic Acids Res."},{"key":"1434_CR22","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.2217\/pgs.09.118","volume":"10","author":"JK Lamba","year":"2009","unstructured":"Lamba, J. K. Genetic factors influencing cytarabine therapy. Pharmacogenomics 10, 1657\u20131674 (2009).","journal-title":"Pharmacogenomics"},{"key":"1434_CR23","doi-asserted-by":"publisher","first-page":"6522","DOI":"10.1038\/onc.2008.316","volume":"27","author":"B Ewald","year":"2008","unstructured":"Ewald, B., Sampath, D. & Plunkett, W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 27, 6522\u20136537 (2008).","journal-title":"Oncogene"},{"key":"1434_CR24","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.molcel.2022.05.004","volume":"82","author":"S Saxena","year":"2022","unstructured":"Saxena, S. & Zou, L. Hallmarks of DNA replication stress. Mol. Cell 82, 2298\u20132314 (2022).","journal-title":"Mol. Cell"},{"key":"1434_CR25","doi-asserted-by":"publisher","first-page":"e18618","DOI":"10.1371\/journal.pone.0018618","volume":"6","author":"B Xu","year":"2011","unstructured":"Xu, B. et al. Replication stress induces micronuclei comprising of aggregated DNA double-strand breaks. PLoS ONE 6, e18618 (2011).","journal-title":"PLoS ONE"},{"key":"1434_CR26","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018100986","volume":"38","author":"SY Mersaoui","year":"2019","unstructured":"Mersaoui, S. Y. et al. Arginine methylation of the DDX5 helicase RGG\/RG motif by PRMT5 regulates resolution of RNA:DNA hybrids. EMBO J. 38, e100986 (2019).","journal-title":"EMBO J."},{"key":"1434_CR27","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrm.2017.67","volume":"18","author":"JC Saldivar","year":"2017","unstructured":"Saldivar, J. C., Cortez, D. & Cimprich, K. A. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat. Rev. Mol. Cell Biol. 18, 622\u2013636 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1434_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","volume":"22","author":"AABA da Costa","year":"2023","unstructured":"da Costa, A. A. B. A., Chowdhury, D., Shapiro, G. I., D\u2019Andrea, A. D. & Konstantinopoulos, P. A. Targeting replication stress in cancer therapy. Nat. Rev. Drug Discov. 22, 38\u201358 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1434_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","volume":"126","author":"Z Qiu","year":"2018","unstructured":"Qiu, Z., Oleinick, N. L. & Zhang, J. ATR\/CHK1 inhibitors and cancer therapy. Radiother. Oncol. 126, 450\u2013464 (2018).","journal-title":"Radiother. Oncol."},{"key":"1434_CR30","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M. & Maitra, A. Pancreatic cancer: advances and challenges. Cell 186, 1729\u20131754 (2023).","journal-title":"Cell"},{"key":"1434_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.rmed.2017.11.015","volume":"134","author":"KG Blyth","year":"2018","unstructured":"Blyth, K. G. & Murphy, D. J. Progress and challenges in Mesothelioma: from bench to bedside. Respir. Med. 134, 31\u201341 (2018).","journal-title":"Respir. Med."},{"key":"1434_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37696-2","volume":"14","author":"M Minoli","year":"2023","unstructured":"Minoli, M. et al. Bladder cancer organoids as a functional system to model different disease stages and therapy response. Nat. Commun. 14, 2214 (2023).","journal-title":"Nat. Commun."},{"key":"1434_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00168-1","volume":"5","author":"GE Wensink","year":"2021","unstructured":"Wensink, G. E. et al. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. npj Precis. Oncol. 5, 30 (2021).","journal-title":"npj Precis. Oncol."},{"key":"1434_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00466-w","volume":"7","author":"M Garioni","year":"2023","unstructured":"Garioni, M. et al. Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer. npj Precis. Oncol. 7, 112 (2023).","journal-title":"npj Precis. Oncol."},{"key":"1434_CR35","doi-asserted-by":"publisher","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","volume":"17","author":"E Mini","year":"2006","unstructured":"Mini, E., Nobili, S., Caciagli, B., Landini, I. & Mazzei, T. Cellular pharmacology of gemcitabine. Ann. Oncol. 17, v7\u2013v12 (2006).","journal-title":"Ann. Oncol."},{"key":"1434_CR36","doi-asserted-by":"publisher","first-page":"200818","DOI":"10.1016\/j.omton.2024.200818","volume":"32","author":"M-A Papadimitriou","year":"2024","unstructured":"Papadimitriou, M.-A. et al. CDKN2A copy number alteration in bladder cancer: Integrative analysis in patient-derived xenografts and cancer patients. Mol. Ther. Oncol. 32, 200818 (2024).","journal-title":"Mol. Ther. Oncol."},{"key":"1434_CR37","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.21873\/anticanres.17351","volume":"44","author":"T Soeta","year":"2024","unstructured":"Soeta, T. et al. MRTX1719, an MTA-cooperative PRMT5 inhibitor, induces cell cycle arrest and synergizes with oxaliplatin and gemcitabine for enhanced anticancer effects. Anticancer Res. 44, 5231\u20135240 (2024).","journal-title":"Anticancer Res."},{"key":"1434_CR38","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","volume":"18","author":"E Lecona","year":"2018","unstructured":"Lecona, E. & Fernandez-Capetillo, O. Targeting ATR in cancer. Nat. Rev. Cancer. 18, 586\u2013595 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"1434_CR39","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1158\/0008-5472.CAN-17-2802","volume":"78","author":"MA Gadhikar","year":"2018","unstructured":"Gadhikar, M. A. et al. CDKN2A\/p16 deletion in head and neck cancer cells is associated with CDK2 activation, replication stress, and vulnerability to CHK1 inhibition. Cancer Res. 78, 781\u2013797 (2018).","journal-title":"Cancer Res."},{"key":"1434_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/srep41950","volume":"7","author":"J Ma","year":"2017","unstructured":"Ma, J. et al. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells. Sci. Rep. 7, 41950 (2017).","journal-title":"Sci. Rep."},{"key":"1434_CR41","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.18632\/oncotarget.2158","volume":"5","author":"AB Hall","year":"2014","unstructured":"Hall, A. B. et al. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget 5, 5674\u20135685 (2014).","journal-title":"Oncotarget"},{"key":"1434_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55316-5","volume":"16","author":"M Gounder","year":"2025","unstructured":"Gounder, M. et al. MAT2A inhibitor AG-270\/S095033 in patients with advanced malignancies: a phase I trial. Nat. Commun. 16, 423 (2025).","journal-title":"Nat. Commun."},{"key":"1434_CR43","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","volume":"30","author":"S Bae","year":"2014","unstructured":"Bae, S., Park, J. & Kim, J.-S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473\u20131475 (2014).","journal-title":"Bioinformatics"},{"key":"1434_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-021-04344-9","volume":"22","author":"DR Stirling","year":"2021","unstructured":"Stirling, D. R. et al. CellProfiler 4: improvements in speed, utility and usability. BMC Bioinform. 22, 433 (2021).","journal-title":"BMC Bioinform."},{"key":"1434_CR45","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. An integrated TCGA Pan-Cancer Clinical Data Resource to drive high-quality survival outcome analytics. Cell. 173, 400\u2013416.e11 (2018).","journal-title":"Cell"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01434-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01434-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01434-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:20:06Z","timestamp":1781742006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01434-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1434"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01434-w","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.M.F. participated in advisory boards or consulted for Astrin Bioscience, Natera, Guardant, Janssen, Gilead, Merck, Immunomedics, and QED Therapeutics, and obtained patent royalties from Immunomedics and Gilead, honoraria from Urotoday, Axiom Healthcare Strategies, and research support from Eli Lilly. Other authors declare no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}